Company announcement, Helsinki, 25 August 2016, at 9:00 am
Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, has decided to terminate its market making agreement with Pareto Securities AB in Nasdaq First North Finland market.
Nexstim Plc has given notice of terminating the market making agreement between Nexstim Plc and Pareto Securities AB in Nasdaq First North Finland. Termination will be effective on 25 October 2016. The market making agreement already in place with Pareto Securities AB in Nasdaq First North Sweden market will continue until further notice.
Martin Jamieson, Chairman & CEO
Further information is available on the website www.nexstim.com or by contacting:
Martin Jamieson, Chairman & CEO email@example.com
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246
Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton firstname.lastname@example.org
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com
Last updated on: 26/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.